tiprankstipranks
Advertisement
Advertisement

PSTV Stock Latest News

Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board
Company AnnouncementsPlus Therapeutics Adds Industry Veteran Ronald Andrews to Board
2d ago
8K
PSTV
Plus Therapeutics’ CNSide assay may reduce healthcare costs
PremiumThe Fly
Plus Therapeutics’ CNSide assay may reduce healthcare costs
9d ago
PSTV
Plus Therapeutics: Advancing Reyobiq Pipeline and CNSide Commercialization Underpinned by Strong Cash Runway to 2027
PremiumRatings
Plus Therapeutics: Advancing Reyobiq Pipeline and CNSide Commercialization Underpinned by Strong Cash Runway to 2027
14d ago
PSTV
Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting
PremiumCompany Announcements
Plus Therapeutics Sets 2026 Virtual Annual Stockholder Meeting
16d ago
8K
PSTV
Plus Therapeutics reports Q4 EPS (29c), consensus (4c)
PremiumThe Fly
Plus Therapeutics reports Q4 EPS (29c), consensus (4c)
16d ago
PSTV
Plus Therapeutics: AMA Code Milestone and 2026 Clinical Catalysts Underpin Buy Rating and $1 Target
PremiumRatingsPlus Therapeutics: AMA Code Milestone and 2026 Clinical Catalysts Underpin Buy Rating and $1 Target
1M ago
PSTV
Plus announces new Category III CPT code for CED used with Reyobiq
Premium
The Fly
Plus announces new Category III CPT code for CED used with Reyobiq
1M ago
PSTV
Is PSTV a Buy, Before Earnings?
Premium
Pre-Earnings
Is PSTV a Buy, Before Earnings?
1M ago
PSTV
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses
PremiumCompany Announcements
Plus Therapeutics Updates Executive Compensation, Approves 2025 Bonuses
1M ago
8K
PSTV
Plus Therapeutics initiated with a Buy at Lake Street
PremiumThe Fly
Plus Therapeutics initiated with a Buy at Lake Street
2M ago
PSTV
Plus Therapeutics price target lowered to $1.50 from $3 at Maxim
PremiumThe Fly
Plus Therapeutics price target lowered to $1.50 from $3 at Maxim
2M ago
PSTV
Plus Therapeutics: Underpenetrated CNSide Commercial Potential and Reyobiq Accelerated-Approval Upside Support Buy Rating into 2026
PremiumRatings
Plus Therapeutics: Underpenetrated CNSide Commercial Potential and Reyobiq Accelerated-Approval Upside Support Buy Rating into 2026
2M ago
PSTV
Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright
PremiumThe FlyPlus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright
2M ago
PSTV
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy
Premium
Company Announcements
Plus Therapeutics Sharpens Focus on CNS Cancer Strategy
2M ago
8K
PSTV
Plus Therapeutics announces anticipated milestones for FY26
Premium
The Fly
Plus Therapeutics announces anticipated milestones for FY26
2M ago
PSTV
Plus Therapeutics completes underwritten public equity offering
PremiumCompany Announcements
Plus Therapeutics completes underwritten public equity offering
2M ago
8K
PSTV
Plus Therapeutics prices 39.5M units at 38c in upsized public offering
PremiumThe Fly
Plus Therapeutics prices 39.5M units at 38c in upsized public offering
2M ago
PSTV
Plus Therapeutics files to sell 22.32M units
PremiumThe Fly
Plus Therapeutics files to sell 22.32M units
3M ago
PSTV
Plus announces completion of Type B meeting with U.S. FDA for REYOBIQ
PremiumThe Fly
Plus announces completion of Type B meeting with U.S. FDA for REYOBIQ
3M ago
PSTV
Buy Rating for Plus Therapeutics: Strategic Advancements and Promising Developments in CNSide Diagnostics and LM Program
PremiumRatingsBuy Rating for Plus Therapeutics: Strategic Advancements and Promising Developments in CNSide Diagnostics and LM Program
4M ago
PSTV
Plus Therapeutics expands CNSide assay platform to State of California
Premium
The Fly
Plus Therapeutics expands CNSide assay platform to State of California
4M ago
PSTV
Plus Therapeutics announces expansion of CNSide Team
Premium
The Fly
Plus Therapeutics announces expansion of CNSide Team
4M ago
PSTV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >